Integra LifeSciences Holdings Corporation $IART Stock Holdings Lifted by Legal & General Group Plc

Legal & General Group Plc raised its stake in Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 52.0% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 368,947 shares of the life sciences company’s stock after buying an additional 126,215 shares during the period. Legal & General Group Plc owned approximately 0.47% of Integra LifeSciences worth $4,582,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of the stock. Systematic Financial Management LP increased its holdings in shares of Integra LifeSciences by 4.5% in the fourth quarter. Systematic Financial Management LP now owns 1,108,599 shares of the life sciences company’s stock valued at $13,769,000 after buying an additional 48,094 shares in the last quarter. Global Retirement Partners LLC bought a new position in shares of Integra LifeSciences in the fourth quarter valued at $25,000. Tejara Capital Ltd increased its holdings in shares of Integra LifeSciences by 42.6% in the fourth quarter. Tejara Capital Ltd now owns 171,813 shares of the life sciences company’s stock valued at $2,134,000 after buying an additional 51,300 shares in the last quarter. Comerica Bank increased its holdings in shares of Integra LifeSciences by 14.6% in the fourth quarter. Comerica Bank now owns 65,946 shares of the life sciences company’s stock valued at $819,000 after buying an additional 8,417 shares in the last quarter. Finally, UBS Group AG increased its holdings in shares of Integra LifeSciences by 211.7% in the fourth quarter. UBS Group AG now owns 408,969 shares of the life sciences company’s stock valued at $5,079,000 after buying an additional 277,745 shares in the last quarter. Institutional investors own 84.78% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on IART shares. Truist Financial dropped their price target on Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating on the stock in a report on Wednesday, April 15th. Wells Fargo & Company lifted their price objective on shares of Integra LifeSciences from $12.00 to $15.00 and gave the stock an “equal weight” rating in a research report on Wednesday, May 6th. Citigroup upgraded shares of Integra LifeSciences from a “sell” rating to a “neutral” rating and lifted their price objective for the stock from $11.00 to $16.00 in a research report on Thursday, May 28th. Weiss Ratings upgraded shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, May 13th. Finally, Argus reiterated a “hold” rating on shares of Integra LifeSciences in a research report on Wednesday, April 15th. Four equities research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus target price of $14.00.

Integra LifeSciences Trading Down 0.3%

NASDAQ IART opened at $16.94 on Tuesday. Integra LifeSciences Holdings Corporation has a 1-year low of $8.70 and a 1-year high of $17.83. The company has a current ratio of 3.38, a quick ratio of 1.95 and a debt-to-equity ratio of 1.75. The company has a market capitalization of $1.32 billion, a PE ratio of -2.62, a price-to-earnings-growth ratio of 1.18 and a beta of 1.24. The firm’s fifty day simple moving average is $12.62 and its 200-day simple moving average is $12.03.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings results on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.13. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 17.42%. The business had revenue of $391.92 million for the quarter, compared to the consensus estimate of $381.81 million. During the same period in the prior year, the business posted $0.41 earnings per share. Integra LifeSciences’s revenue for the quarter was up 2.4% compared to the same quarter last year. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. As a group, sell-side analysts anticipate that Integra LifeSciences Holdings Corporation will post 2.44 earnings per share for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.